insulin News
Most Popular insulin Story
Insulin drugs could lose $6.1B to biosimilars
What class of drugs is most vulnerable to biosimilar competition? If you said diabetes meds, then you're right. That's because biosimilar insulins and insulin analogues are easy to develop and make, Read more...
Latest Headlines
- December 7, 2011
- November 30, 2011
- August 4, 2011
- March 9, 2011
- February 11, 2011
- October 14, 2009
- November 12, 2007
- October 23, 2007
- August 30, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
